Opioid 'Data Warehouse' Is Part Of US FDA's New Controlled Substances Program
CDER-based program lead by Marta Sokolowska will also handle benzodiazepine and stimulants activities and consult on relevant application assessments.
You may also be interested in...
The move should increase the visibility of the FDA’s wide-ranging, and widely criticized, opioid epidemic response.
FDA and NIH are looking to spark research on approaches to reduce use of benzodiazepines and to help mitigate issues with withdrawal associated with the widely prescribed therapies.
Additional power would allow the agency to punish 'simple' REMS violations and improve administration of risk management programs, according to a new report looking at FDA's oversight of opioids.